{"schema_version":"secwatch.filing_event.v1","accession":"0001420800-23-000003","form_type":"8-K","ticker":"ENOV","cik":"0001420800","company_name":"Enovis CORP","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.869917+00:00","generated_at":"2026-06-19T02:21:04.300132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enovis Q4 net loss $0.71/sh, adj EPS $0.72; FY22 sales up 10% to $1.6B; guides FY23 adj EPS $2.15-2.30","bullets":["Q4 net sales $409M (+2% YoY, +5% organic); Reconstructive segment organic growth 14%.","Q4 adj EBITDA $75M (18.3% of sales), +290 bps YoY; full-year adj EBITDA margin 15.1% (+70 bps).","FY22 net loss from continuing ops $38M ($0.25/diluted); adj EPS $2.27, up 15% YoY.","FY23 guidance: organic revenue growth 5-6%, adj EBITDA $255-265M, adj EPS $2.15-2.30.","Acquired Insight Medical Systems (ARVIS augmented reality) in 2022; acquisitions delivered double-digit organic growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001420800-23-000003","json":"https://secwatch.observer/filing/0001420800-23-000003.json","markdown":"https://secwatch.observer/filing/0001420800-23-000003.md","text":"https://secwatch.observer/filing/0001420800-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/cfx-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:21:04.300132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d88e543840976598d912bd706e913698190162a","claim":"Enovis CORP reported the fourth quarter ended December 31, 2022 results: revenue $409 million, net income net loss from continuing operations of $55 million, or $0.71 per diluted share, EPS $0.72.","evidence_excerpt":"• Completed first year as independent Med Tech growth company with sales growth of 10%, organic growth of 6% and EBITDA margin expansion • Grew fourth quarter sales 2% to $409 million, with 5% organic growth over the prior year quarter, and double-digit growth performance in its Reconstructive segment • Reported a fourth quarter net loss from continuing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$409 million"},{"label":"Net income","value":"net loss from continuing operations of $55 million, or $0.71 per diluted share"},{"label":"EPS","value":"$0.72"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6ecbaf151b1bba1cbaf1013e603bba7433d30d9d","claim":"Enovis CORP reported the 2022 fiscal year results: revenue $1.6 billion, net income net loss from continuing operations of $38 million, or $0.25 per diluted share, EPS $2.27. Guidance initiated.","evidence_excerpt":"segment grew 12%, and 14% on an organic basis, and its Prevention and Recovery segment declined 2% with 1% organic growth. For the 2022 fiscal year, net sales grew 10% to $1.6 billion, with organic growth of 6%. Enovis also reported a fourth quarter operating loss of $28 million or 6.9% of sales, and adjusted EBITDA of $75 million, or 18.3% of sales, an","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the 2022 fiscal year"},{"label":"Revenue","value":"$1.6 billion"},{"label":"Net income","value":"net loss from continuing operations of $38 million, or $0.25 per diluted share"},{"label":"EPS","value":"$2.27"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}